You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
安進:新肺癌治療藥Lumakras有效減少後期肺癌病人病情惡化風險34%
格隆匯 09-12 18:01
格隆匯9月12日 | 美國安進藥廠(AMGN.US)表示,臨牀實驗顯示,新肺癌治療藥Lumakras相對於化療,更有效減少後期肺癌病人的病情惡化風險34%。美國FDA去年已經批准Lumakras可應用於部分指定的肺癌患者,而安進本次的研究是希望評估Lumakras是否較化療更有效幫助後期肺癌病人阻止病情惡化。雖然實驗證明Lumakras是有效的,但也顯示,兩項治療本次的臨牀實驗結果在整體生存率方面沒有明顯分別。安進表示,將提交本次對345名病人進行臨牀實驗的數據予FDA參考,也會提交予歐盟藥物管理局參考。安進正研究Lumakras對初期肺癌病人是否有幫助。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account